Retatrutide Phase 2 Results: The Triple Agonist Delivering 24% Weight Loss

AI generatedWeight LossGLP-1Clinical Trials
This article was AI-generated for informational purposes only. It is not medical advice. Always verify claims with the cited sources.

The incretin-based obesity pharmacotherapy landscape has evolved rapidly — from single GLP-1 receptor agonists like semaglutide, to dual agonists like tirzepatide, and now to a triple-hormone approach that may redefine the upper boundary of pharmacological weight loss. Retatrutide (LY3437943), developed by Eli Lilly, is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Its Phase 2 trial results, published in The New England Journal of Medicine in 2023, demonstrated unprecedented weight reductions that have captured the attention of obesity researchers and endocrinologists worldwide.

What Makes Retatrutide a Triple Agonist?

Retatrutide is a single-chain peptide that activates three distinct G protein-coupled receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This tri-agonist design builds on the dual GLP-1/GIP mechanism of tirzepatide by adding glucagon receptor activation — a component that had previously been explored cautiously due to glucagon's well-known hyperglycemic effects.

The rationale for including glucagon signaling is rooted in its metabolic effects beyond glucose. Glucagon receptor activation increases energy expenditure, promotes hepatic lipid oxidation, and reduces hepatic fat content. Ambery et al., 201830024-X) demonstrated in earlier proof-of-concept work that GLP-1/glucagon co-agonism could produce meaningful weight loss while the GLP-1 component counterbalanced glucagon's glycemic effects.

Retatrutide's structure is based on a modified GIP peptide backbone with engineered activity at all three receptors. Its pharmacokinetic profile supports once-weekly subcutaneous dosing, similar to tirzepatide and semaglutide. The relative potency across the three receptors has been optimized to maximize metabolic benefits while maintaining glycemic safety — a delicate balancing act that defines much of the tri-agonist design challenge.

The Phase 2 Trial Design

The pivotal Phase 2 trial was a 48-week, randomized, double-blind, placebo-controlled study that enrolled 338 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity) without diabetes. Results were published by Jastreboff et al., 2023 in The New England Journal of Medicine.

Participants were randomized to one of several retatrutide dose groups (1 mg, 4 mg, 8 mg, or 12 mg, with some dose-escalation variations) or placebo. The primary endpoint was percent change in body weight from baseline at 24 weeks, with a key secondary endpoint at 48 weeks. All groups received lifestyle counseling but no additional dietary intervention beyond standard guidance.

A parallel study evaluated retatrutide in adults with type 2 diabetes, published simultaneously by Rosenstock et al., 2023, broadening the dataset across metabolic phenotypes.

Weight Loss Results: Record-Setting Efficacy

The headline finding was striking. At the highest dose (12 mg), participants achieved a mean weight loss of -24.2% at 48 weeks — a figure that surpasses results from any previously published monotherapy trial for obesity.

The dose-response relationship was clear and consistent:

  • Placebo: −2.1% weight loss at 48 weeks
  • 1 mg retatrutide: −8.7% weight loss
  • 4 mg retatrutide (escalated from 2 mg): −17.1% weight loss
  • 8 mg retatrutide (escalated from 4 mg): −22.8% weight loss
  • 12 mg retatrutide (escalated from 4 mg): −24.2% weight loss

    • At the 12 mg dose, over 90% of participants lost at least 5% of their body weight, and roughly 26% achieved ≥30% weight loss — a threshold approaching outcomes typically associated with bariatric surgery. For context, semaglutide 2.4 mg produced approximately -15.3% weight loss at 68 weeks in the STEP 1 trial (Wilding et al., 2021), while tirzepatide 15 mg achieved -20.9% at 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022).

    It is worth noting that direct cross-trial comparisons are inherently limited due to differences in trial duration, populations, and design. However, the magnitude of weight loss with retatrutide at 48 weeks — with weight curves still trending downward at study end — suggests the ceiling may not yet have been reached.

    Metabolic Benefits Beyond the Scale

    Weight loss of this magnitude predictably improves cardiometabolic risk markers, and retatrutide's Phase 2 data confirmed this across multiple parameters.

    Participants in the 12 mg group showed significant improvements in:

  • Waist circumference: reductions exceeding 18 cm on average
  • Systolic blood pressure: meaningful decreases versus placebo
  • Triglycerides and lipid profiles: dose-dependent improvements
  • Fasting insulin and HOMA-IR: consistent with improved insulin sensitivity

    • The parallel diabetes trial by Rosenstock et al., 2023 showed that retatrutide reduced HbA1c by up to 2.02 percentage points at the 12 mg dose, with over 70% of participants achieving HbA1c below 5.7% — the threshold for normoglycemia. This degree of glycemic normalization is remarkable and suggests the glucagon component does not meaningfully impair glucose control when combined with potent incretin signaling.

    Perhaps most intriguingly, exploratory analyses have indicated that retatrutide produces substantial reductions in hepatic fat content. A sub-study using MRI-based proton density fat fraction (MRI-PDFF) measurements showed that approximately 86% of participants with baseline metabolic dysfunction-associated steatotic liver disease (MASLD) achieved normalization of liver fat at the 48-week mark (Sanyal et al., 2024). This finding has generated significant interest given the lack of broadly approved pharmacotherapies for MASLD/MASH.

    Safety and Tolerability Profile

    The adverse event profile of retatrutide was broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal events being the most frequently reported side effects.

    Key safety observations included:

  • Nausea occurred in up to 45% of participants in the highest dose groups during escalation, generally mild to moderate and transient
  • Diarrhea and vomiting were also dose-dependent but manageable with slow titration
  • Discontinuation rates due to adverse events were relatively low (approximately 6% across active doses), comparable to tirzepatide trials
  • No significant signals for pancreatitis, medullary thyroid carcinoma, or major adverse cardiovascular events emerged, though Phase 2 was not powered for rare events

    • The dose-escalation strategy — starting at 2 mg or 4 mg before reaching maintenance doses — appeared to attenuate gastrointestinal side effects substantially. Heart rate increases of 2–4 bpm were observed, consistent with GLP-1 receptor agonist class effects. No clinically significant hypoglycemia was reported in the non-diabetic cohort.

    Long-term safety data from Phase 3 trials will be essential to fully characterize the risk profile, particularly regarding the glucagon receptor component's effects on hepatic glucose output, bone density, and lean mass preservation.

    Phase 3 Program and What Lies Ahead

    Eli Lilly has initiated a comprehensive Phase 3 program called TRIUMPH, which includes multiple trials across obesity, type 2 diabetes, and MASLD/MASH populations. The obesity registration trials (NCT05929066) are enrolling thousands of participants with primary endpoints at 72 weeks, which will provide the definitive efficacy and safety data needed for regulatory submissions.

    Key open questions that Phase 3 will need to address include:

  • Whether the -24.2% weight loss observed at 48 weeks extends further with longer treatment
  • Long-term cardiovascular outcomes and potential MACE benefit
  • Body composition effects — specifically whether the glucagon component preferentially targets fat mass while preserving lean mass
  • Durability of weight loss and the trajectory of weight regain upon discontinuation
  • Comparative efficacy against tirzepatide in head-to-head trials

    • The MASLD/MASH indication (NCT06251856) represents a potentially transformative application, as the combination of weight loss, direct glucagon-mediated hepatic fat oxidation, and improved insulin sensitivity creates a compelling mechanistic rationale for liver-specific benefits.

    Key Takeaways

  • Retatrutide is a first-in-class GLP-1/GIP/glucagon triple agonist that achieved -24.2% mean weight loss at 48 weeks in its Phase 2 obesity trial — the highest reported for any anti-obesity monotherapy to date.
  • The glucagon receptor component differentiates retatrutide from dual agonists like tirzepatide, contributing to increased energy expenditure and dramatic reductions in hepatic fat content.
  • Gastrointestinal side effects were the most common adverse events, consistent with the incretin class, and were generally manageable with dose escalation.
  • Liver fat normalization in ~86% of MASLD participants suggests retatrutide may have significant therapeutic potential beyond obesity and diabetes.
  • Phase 3 TRIUMPH trials are underway, with results expected to clarify long-term efficacy, safety, and whether retatrutide can maintain its Phase 2 performance at scale.
    • Not medical advice. For research purposes only. Consult a licensed physician before beginning any protocol.
    Retatrutide Phase 2 Results: The Triple Agonist Delivering 24% Weight Loss — PepStash Blog · PepStash